Thursday, 5 November 2026European Markets

VIRBAC Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with virbac (virp.pa) jumping 10.69% to €336.50 on tuesday while cac 40 jumped 0.08% to €7,574.67.

virbac's last close was €304.00, 3.18% below its 52-week high of €314.00.

about virbac

virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.

earnings per share

as for profitability, virbac has a trailing twelve months eps of €14.14.

pe ratio

virbac has a trailing twelve months price to earnings ratio of 23.8. meaning, the purchaser of the share is investing €23.8 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.8%.

revenue growth

year-on-year quarterly revenue growth declined by 1%, now sitting on 1.21b for the twelve trailing months.

yearly top and bottom value

virbac's stock is valued at €336.50 at 21:36 est, higher than its 52-week high of €314.00.

dividend yield

according to morningstar, inc., the next dividend payment is on jun 26, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.49%.

volume

today's last reported volume for virbac is 9081 which is 63.09% above its average volume of 5568.

more news about virbac (virp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com